文献速递生殖医学妇科

年轻乳腺癌女性的无病生存率不因生育力保存技术而异

Disease-free survival does not differ according to fertility preservation technique for young women with breast cancer.
PubMed 文献 · Fertil Steril · 2022-12-05

这项回顾性双中心队列研究纳入740例18-43岁局部乳腺癌患者,比较接受卵巢刺激(STIM组328例)与未接受激素给药(no STIM组412例)的生育力保存技术后的长期无病生存和总生存。中位随访至2021年5月,4年无病生存率STIM组87.9% vs no STIM组83.1%,校正后复发风险无显著差异(HR 0.83,95%CI 0.64-1.08);4年总生存率STIM组97.6% vs no STIM组93.6%,校正后死亡风险STIM组显著更低(HR 0.55,95%CI 0.35-0.85)。作者结论认为卵巢刺激未显著影响无病生存,但与更高总生存相关,因死亡和复发为罕见事件,结果需谨慎对待。

要点

  • 4年无病生存率STIM组87.9% vs no STIM组83.1%,校正后复发风险无显著差异(HR 0.83,95%CI 0.64-1.08)。
  • 4年总生存率STIM组97.6% vs no STIM组93.6%,校正后死亡风险STIM组显著更低(HR 0.55,95%CI 0.35-0.85)。
  • 作者认为因死亡和复发为罕见事件,结果需谨慎对待。

核心结论

  • 在该队列中,乳腺癌患者生育力保存使用卵巢刺激未显著影响无病生存,但与更高总生存相关。
  • 年轻乳腺癌患者的无病生存和总生存不受生育力保存技术影响,与化疗时机(新辅助或辅助)及是否使用卵巢刺激无关。
  • 因死亡和复发为罕见事件,这些结果需谨慎对待。

研究设计与样本

  • 回顾性双中心队列研究,设置于两所大学医院。
  • 纳入740例18-43岁局部乳腺癌患者,于2013年至2019年确诊后接受初次生育力保存。
  • 328例接受至少1个卵巢刺激周期(STIM组),412例接受无激素给药技术(no STIM组)。
  • 主要结局为至2021年5月的无病生存和总生存,采用log-rank检验比较,Cox比例风险回归模型进行多变量分析。

主要发现

  • 740例中随访数据可用者STIM组269例(82%)、no STIM组330例(80%)。
  • 4年无病生存率Kaplan-Meier估计STIM组87.9%(82.8%-92.2%)vs no STIM组83.1%(78.4%-87.3%)。
  • 校正预后参数后,STIM组与no STIM组乳腺癌复发率无显著差异(HR 0.83,95%CI 0.64-1.08)。
  • 4年总生存率Kaplan-Meier估计STIM组97.6%(95.3%-99.2%)vs no STIM组93.6%(90.9%-95.9%),log-rank检验STIM组高于no STIM组。
  • 校正预后参数后,STIM组死亡风险仍显著低于no STIM组(HR 0.55,95%CI 0.35-0.85)。

局限性

  • 死亡和复发为罕见事件,这些结果应谨慎对待。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study whether fertility preservation strategies using ovarian stimulation or without using it impact long-term disease-free survival of patients with breast cancer. DESIGN: Retrospective bicentric cohort study. SETTING: Two university hospitals. PATIENT(S): In this study, 740 women with breast cancer, aged 18-43 years, who received primary fertility preservation between 2013 and 2019 after a diagnosis of localized breast cancer were included. INTERVENTION(S): Overall, 328 patients underwent at least 1 ovarian stimulation cycle (STIM group) and 412 had a technique without hormonal administration (no STIM group). MAIN OUTCOME MEASURE(S): Disease-free survival and overall survival up to May 2021 were compared between the 2 groups by log-rank test. Cox proportional-hazard regression model was used for multivariable analyses. RESULT(S): Out of the 740 women who underwent fertility preservation, follow-up data were available for 269 women in the STIM group (82%) and 330 (80%) in the no STIM group. Kaplan-Meier estimates of disease-free survival at 4 years were 87.9% (82.8%-92.2%) and 83.1% (78.4%-87.3%) in the STIM and no STIM groups, respectively. After adjustment on prognostic parameters, no significant difference in breast cancer recurrence rate was observed between the STIM and no STIM groups (hazard ratios, 0.83 [0.64-1.08]). Kaplan-Meier estimate of overall survival at 4 years was 97.6% (95.3%-99.2%) and 93.6% (90.9%-95.9%) in the STIM and no STIM groups, respectively. Overall survival was higher in the STIM group than no STIM group (log-rank test). After adjustment on prognostic parameters, the risk of death remained significantly lower in the STIM group (Hazard Ratio, 0.55 [0.35-0.85]). CONCLUSION(S): In our cohort, STIM for fertility preservation in breast cancer did not significantly impact disease-free survival but was associated with higher overall survival. The disease-free survival and overall survival of young patients with breast cancer were not impacted by fertility preservation techniques irrespective of the timing of chemotherapy (neoadjuvant or adjuvant) and the use of ovarian stimulation. Nevertheless, because death and recurrence were rare events, these results should be taken with caution.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Sonigo C, Amsellem N, Mayeur A, et al. Disease-free survival does not differ according to fertility preservation technique for young women with breast cancer. Fertil Steril. 2022. PMID: 36473609. doi:10.1016/j.fertnstert.2022.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。